ClinicalTrials.gg
CompletedNCT03305159Updated Jun 27, 2019Results posted

Tolerance of Chlorhexidine Gluconate Vaginal Cleansing Solution

A Phase 4 interventional study of Povidone-Iodine and 4% Chlorhexidine Gluconate in Surgical Preparation of the Vagina, sponsored by Northwestern University. Completed at 1 site in United States. Open to female participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-06-27.

Sponsored by Northwestern University · Phase 4, Interventional, and Other

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
134
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Study summary

Conduct a randomized control study to compare the tolerance of 4% chlorhexidine gluconate/4% isopropyl alcohol versus povidone iodine vaginal cleansing solutions for surgical preparations of the vagina. Patients will be randomized to either control (povidone iodine) or experimental (chlorhexidine gluconate), and then be given a short survey prior to and immediately after surgery, and again 24-48 hours via phone asking them about the presence and severity of vaginal dryness, burning, itchiness, unusual vaginal discharge, and pain or burning with urination.

Read the detailed description

Surgical site antisepsis is critical in preventing surgical site infections. Although chlorhexidine gluconate has proven to be superior to povidone iodine for surgical site antisepsis, povidone iodine is the only FDA-approved antiseptic solution for surgical preparation of the vagina. Many surgeons are hesitant to use chlorhexidine gluconate for preoperative vaginal cleansing due to the alcohol dissolvent present in the solutions that is implicated in a greater risk of irritation. Yet, there has been no randomized study to illustrate whether the risk of vaginal irritation is greater in chlorhexidine gluconate versus povidone iodine. Thus, the purpose of the study is to conduct a randomized control trial to compare the tolerance of 4% chlorhexidine gluconate to povidone iodine using patient-reported outcomes of vaginal or urinary symptoms. Patients will be randomized to either control or experimental, and then be given a short survey prior to and immediately after surgery, and again 24-48 hours via phone asking them about the presence and severity of vaginal dryness, burning, itchiness, unusual vaginal discharge, and pain or burning with urination.

02

Conditions studied

  • Surgical Preparation of the Vagina
03

In context

Lead sponsor

Northwestern University is the lead sponsor of 1,424 studies on the registry; 199 are open to participants now.

Of its 105 completed or terminated interventional studies of FDA-regulated products, 78 (74%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Undergoing hysteroscopy
  2. Gynecologic dilation \& curettage
  3. Endometrial ablation
  4. Essure without concomitant laparoscopy

Exclusion criteria

Exclusion Criteria:

  1. Pregnant
  2. Have a history of atopic dermatitis, vaginal irritation, allergic reactions, or anaphylaxis to chlorhexidine gluconate or povidone iodine.
05

Study design

Phase
Phase 4
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
134 participants (actual)

Study arms

  • Active comparator
    Control (Povidone Iodine)

    Patients to receive povidone iodine for the surgical preparation of the vagina.

    Drug: Povidone-Iodine

  • Experimental
    Intervention (4% Chlorhexidine gluconate)

    Patients to receive 4% chlorhexidine gluconate for the surgical preparation of the vagina.

    Drug: 4% Chlorhexidine Gluconate

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Participants With Vaginal or Urinary Symptoms After Surgery, Assessed by Validated Questionnaire (Modified PRO-CTCAE)

    To determine and compare the number of participants with vaginal or urinary symptoms after treatment with chlorhexidine gluconate versus povidone iodine vaginal cleansing solutions.

    Time frame: Day of surgery to 24-48 hours after surgery

07

Results

Posted Jun 27, 2019
Limitations and caveats
Single-blinded design. Present study included participants undergoing hysteroscopic procedures these procedures themselves may certainly influence postoperative irritative symptoms. Loss of follow-up both immediately and 24-48 hours postoperative.

Participant flow

Participant flow — Overall Study
MilestoneControl (Povidone Iodine)Intervention (4% Chlorhexidine Gluconate)
Started6668
Completed6360
Not completed38

Outcome measures

PrimaryNumber of Participants With Vaginal or Urinary Symptoms After Surgery, Assessed by Validated Questionnaire (Modified PRO-CTCAE)

To determine and compare the number of participants with vaginal or urinary symptoms after treatment with chlorhexidine gluconate versus povidone iodine vaginal cleansing solutions.

Time frame:
Day of surgery to 24-48 hours after surgery
Reported as:
Count of participants · Participants
Number of Participants With Vaginal or Urinary Symptoms After Surgery, Assessed by Validated Questionnaire (Modified PRO-CTCAE)
ParticipantsControl (Povidone Iodine)Intervention (4% Chlorhexidine Gluconate)
Vaginal dryness411
Vaginal burning825
Unusual vaginal discharge1014
Pain of burning with urination917
Vaginal itchiness77

Adverse events

Collected over Data were collected for each patient immediately postoperatively to 24-48 hours postoperatively.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Control (Povidone Iodine)0/63 (0%)0/63 (0%)0/63 (0%)
Intervention (4% Chlorhexidine Gluconate)0/60 (0%)0/60 (0%)1/59 (1.7%)
Most frequent other events
Most frequent other events
EventControl (Povidone Iodine)Intervention (4% Chlorhexidine Gluconate)
Severe SwellingSkin and subcutaneous tissue disorders0/631/59

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Control (Povidone Iodine)Intervention (4% Chlorhexidine Gluconate)Total
<=18 years000
Between 18 and 65 years5959118
>=65 years415
Age, Continuous
Age, Continuous(years)Control (Povidone Iodine)Intervention (4% Chlorhexidine Gluconate)Total
Mean46 ± 1044 ± 945 ± 9.7
Sex: Female, Male
Sex: Female, Male(Participants)Control (Povidone Iodine)Intervention (4% Chlorhexidine Gluconate)Total
Female6360123
Male000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Control (Povidone Iodine)Intervention (4% Chlorhexidine Gluconate)Total
American Indian or Alaska Native000
Asian426
Native Hawaiian or Other Pacific Islander000
Black or African American8917
White413980
More than one race000
Unknown or Not Reported101020
Region of Enrollment
Region of Enrollment(participants)Control (Povidone Iodine)Intervention (4% Chlorhexidine Gluconate)Total
United States6360123
08

Study locations

1 site
  • Prentice Women's Hospital - Northwestern Memorial Hospital
    Chicago, Illinois 60611, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Undecided

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2017 to primary completion in Apr 2018, 8 months.

Results were first posted in Jun 2019, 1 year 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 4, 2017
First posted
Oct 9, 2017
StartActual
Aug 1, 2017
Primary completionActual
Apr 1, 2018
CompletionActual
Apr 15, 2018
Results first posted
Jun 27, 2019
Last update
Jun 27, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 27, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03305159
Responsible party
Magdy Milad, MD (Principal Investigator, Northwestern University) — Principal investigator
First posted
Oct 9, 2017
Start date
Aug 1, 2017
Primary completion
Apr 1, 2018
Completion
Apr 15, 2018
Results posted
Jun 27, 2019
Last update
Jun 27, 2019

Study contacts

Magdy Milad, MD
principal investigator · Northwestern University

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Chlorhexidine gluconate

Start the discussion